MAXCYTE (NASDAQ: MXCT) director receives RSU and option grants as annual equity award

Rhea-AI Filing Summary

MAXCYTE, INC. director Douglas Richard reported awards of restricted stock units and stock options as part of his compensation. He acquired 30,421 RSUs, each representing one future share of common stock, and 49,579 stock options to buy common shares at $1.13 per share.

The annual grants were made under the company’s equity grant policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, assuming he continues to serve. After the RSU grant, his direct common stock holdings total 260,998 shares.

Insights

Equity compensation analyst

Routine director equity grants with no cash trading activity.

Director Douglas Richard received 30,421 restricted stock units and 49,579 stock options with a $1.13 exercise price as part of MAXCYTE, INC.’s equity grant policy for non-employee directors. These are compensation awards, not open-market trades.

The RSUs vest on June 17, 2027, conditioned on continued service, tying his incentives to longer-term company performance. The options expire in 2036, creating a long-dated incentive to increase the stock price above $1.13 before expiration.

Such grants are typical for directors and do not by themselves signal a change in outlook. The filing shows no sales, gifts, or tax-withholding dispositions, and derivativeSummary is empty after the grant, indicating only newly awarded options are reported here.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DOUGLAS RICHARD

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	49,579	$0.00	--
Grant/Award	Common Stock	30,421	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 49,579 shares (Direct, null); Common Stock — 260,998 shares (Direct, null)

Footnotes (1)

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Key Figures

RSU grant: 30,421 RSUs Stock options granted: 49,579 options Option exercise price: $1.13 per share +2 more

5 metrics

RSU grant 30,421 RSUs Annual equity grant to non-employee director on June 17, 2026

Stock options granted 49,579 options Director stock option grant on June 17, 2026

Option exercise price $1.13 per share Strike price for newly granted stock options

Common shares after grant 260,998 shares Director’s direct common stock holdings following RSU grant

Option expiration June 16, 2036 Expiration date of the newly granted stock options

Key Terms

restricted stock units ("RSUs"), Equity Grant Policy, non-employee directors, contingent right, +1 more

5 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Equity Grant Policy financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

non-employee directors financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Stock Option (right to buy) financial

"Stock Option (right to buy) listed as a derivative security with an exercise price of $1.1300."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DOUGLAS RICHARD

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		30,421(1)(2)	A	$0	260,998	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.13	06/17/2026		A		49,579		(2)	06/16/2036	Common Stock	49,579	$0	49,579	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

	/s/ Maher Masoud, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did MAXCYTE (MXCT) director Douglas Richard receive in this Form 4 filing?

Douglas Richard received equity compensation awards: 30,421 restricted stock units and 49,579 stock options in MAXCYTE common stock. These awards increase his potential ownership and align his interests with shareholders over time rather than reflecting any open-market share purchases or sales.

At what price can the new MAXCYTE (MXCT) stock options be exercised?

The newly granted stock options have an exercise price of $1.13 per share. This means Douglas Richard can choose to buy MAXCYTE common stock at $1.13, if and when the options vest and before their expiration date, provided standard conditions are met.

When do Douglas Richard’s MAXCYTE (MXCT) RSUs from this grant vest?

The shares underlying this annual grant vest on June 17, 2027. Vesting is contingent on Douglas Richard’s continuous service as a non-employee director through that date, which encourages longer-term board engagement and alignment with company performance over several years.

How many MAXCYTE (MXCT) common shares does Douglas Richard hold after this Form 4?

Following the reported RSU grant, Douglas Richard is shown holding 260,998 shares of MAXCYTE common stock directly. This figure reflects his post-transaction position in the underlying common stock, separate from the additional stock options granted in this filing.

Is this MAXCYTE (MXCT) Form 4 a stock purchase or sale by Douglas Richard?

No open-market purchase or sale occurred in this Form 4. The transactions are coded as grants or awards, meaning Douglas Richard acquired RSUs and options as compensation rather than buying or selling shares for cash in the market.

Are the MAXCYTE (MXCT) director equity grants part of a policy?

Yes. The filing states this annual grant was made under MAXCYTE’s Equity Grant Policy for non-employee directors. That indicates a structured, recurring compensation program rather than a one-time, discretionary equity award for Douglas Richard.